Abstract
Study design:
Lithium has attracted much attention as a neuroregenerative agent for spinal cord injury in animal models. We hypothesized that the lithium can be beneficial to patients with spinal cord injury. The safety and pharmacokinetics of lithium has been studied in our earlier phase I clinical trial, indicating its safety. This is a phase II clinical trial to evaluate its efficacy on chronic spinal cord injury patients.
Objectives:
The aim of this study was to investigate the efficacy of lithium on chronic spinal cord injury patients.
Setting:
A major spinal cord injury rehabilitation center in Beijing, China.
Methods:
Randomized, double-blind, placebo-controlled 6-week parallel treatment arms with lithium carbonate and with placebo. A total of 40 chronic spinal cord injury subjects were recruited. Oral lithium carbonate was titrated or placebo was simulated to maintain the serum lithium level of 0.6–1.2 mmol l−1 for 6 weeks, followed by a 6-month follow-up. The functional outcomes and the neurological classifications, as well as the safety parameters, adverse events and pharmacokinetic data were carefully collected and monitored.
Results:
No significant changes in the functional outcomes and the neurological classifications were found. The only significant differences were in the pain assessments using visual analog scale comparing the lithium and the placebo group. No severe adverse event was documented in the study.
Conclusion:
The lithium treatment did not change the neurological outcomes of patients with chronic spinal cord injury. It is worth to investigate whether lithium is effective in the treatment of neuropathic pain in chronic spinal cord injury.
Sponsorship:
China Spinal Cord Injury Network Company Limited.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Yick LW, So KF, Cheung PT, Wu WT . Lithium chloride reinforces the regeneration-promoting effect of chondroitinase ABC on rubrospinal neurons after spinal cord injury. J Neurotrauma 2004; 21: 932–943.
Wong YW, Tam S, So KF, Chen JY, Cheng WS, Luk KD et al. A three-month, open-label, single-arm trial evaluating the safety and pharmacokinetics of oral lithium in patients with chronic spinal cord injury. Spinal Cord 2011; 49: 94–98.
Zhao YD, Rahardja D, Qu Y . Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties. Stat Med 2008; 27: 462–468.
Wexler EM, Geschwind DH, Palmer TD . Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 2008; 13: 285–292.
Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM . Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 2003; 117: 55–61.
De Boer J, Wang HJ, Van Blitterswijk C . Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng 2004; 10: 393–401.
De Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, van Blitterswijk C . Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 2004; 34: 818–826.
Levitt LJ, Quesenberry PJ . The effect of lithium on murine hematopoiesis in a liquid culture system. N Engl J Med 1980; 302: 713–719.
Aglietta M, Leone A, Piacibello W . Effect of lithium on normal and chronic granulocytic leukemia colony forming cells (CFU-GM). Experientia 1981; 37: 1340–1341.
Gallicchio VS, Chen MG . Influence of lithium on proliferation of hematopoietic stem cells. Exp Hematol 1981; 9: 804–810.
Anton R, Kestler HA, Kuhl M . Beta-catenin signaling contributes to stemness and regulates early differentiation in murine embryonic stem cells. FEBS Lett 2007; 581: 5247–5254.
Schmidt MM, Guan K, Wobus AM . Lithium influences differentiation and tissue-specific gene expression of mouse embryonic stem (ES) cells in vitro. Int J Dev Biol 2001; 45: 421–429.
Ohteki T, Parsons M, Zakarian A, Jones RG, Nguyen LT, Woodgett JR et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 2000; 192: 99–104.
Willing AE, Zigova T, Milliken M, Poulos S, Saporta S, McGrogan M et al. Lithium exposure enhances survival of NT2N cells (hNT neurons) in the hemiparkinsonian rat. Eur J Neurosci 2002; 16: 2271–2278.
Vanelderen P, Rouwette T, Kozicz T, Roubos E, Van Zundert J, Heylen R et al. The role of brain-derived neurotrophic factor in different animal models of neuropathic pain. Eur J Pain 2010; 14: 473 e1-9.
Jing YY, Wang JY, Li XL, Wang ZH, Pei L, Pan MM et al. Nerve growth factor of red nucleus involvement in pain induced by spared nerve injury of the rat sciatic nerve. Neurochem Res 2009; 34: 1612–1618.
Shimizu T, Shibata M, Wakisaka S, Inoue T, Mashimo T, Yoshiya I . Intrathecal lithium reduces neuropathic pain responses in a rat model of peripheral neuropathy. Pain 2000; 85: 59–64.
Jurgens TP, Schaefer C, May A . Treatment of cluster headache in pregnancy and lactation. Cephalalgia 2009; 29: 391–400.
Matharu M, Silver N . Cluster headache. Clin Evid (Online) 2008.
Leroux E, Ducros A . Cluster headache. Orphanet J Rare Dis 2008; 3: 20.
Loder E . Prophylaxis: headaches that never happen. Headache 2008; 48: 694–696.
Karakucuk EH, Yamanoglu T, Demirel O, Bora N, Zengil H . Temporal variation in drug interaction between lithium and morphine-induced analgesia. Chronobiol Int 2006; 23: 675–682.
Johnston IN, Westbrook RF . Inhibition of morphine analgesia by lithium: role of peripheral and central opioid receptors. Behav Brain Res 2004; 151: 151–158.
Zhang LJ, Han NL, Han JS . Regulation by lithium of the antagonistic effect of cholecystokinin octapeptide on ohmefentanyl-induced antinociception. Neuropharmacology 1994; 33: 123–126.
Kim J, Kim JH, Kim Y, Cho HY, Hong SK, Yoon YW . Role of spinal cholecystokinin in neuropathic pain after spinal cord hemisection in rats. Neurosci Lett 2009; 462: 303–307.
Maier SF, Wiertelak EP, Martin D, Watkins LR . Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 1993; 623: 321–324.
Cirillo G, Cavaliere C, Bianco MR, De Simone A, Colangelo AM, Sellitti S et al. Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain. Cell Mol Neurobiol 2010; 30: 51–62.
Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M . Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther 2002; 9: 1387–1395.
Tender GC, Kaye AD, Li YY, Cui JG . Neurotrophin-3 and Tyrosine-Kinase C Have Modulatory Effects on Neuropathic Pain in the Rat Dorsal Root Ganglia. Neurosurgery 2011; 68: 1048–1055.
Wilson-Gerwing TD, Stucky CL, McComb GW, Verge VM . Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol 2008; 213: 303–314.
Chen Q, Smith GM, Shine HD . Immune activation is required for NT-3-induced axonal plasticity in chronic spinal cord injury. Exp Neurol 2008; 209: 497–509.
Ramer LM, McPhail LT, Borisoff JF, Soril LJ, Kaan TK, Lee JH et al. Endogenous TrkB ligands suppress functional mechanosensory plasticity in the deafferented spinal cord. J Neurosci 2007; 27: 5812–5822.
Young W . Review of lithium effects on brain and blood. Cell Transplant 2009; 18: 951–975.
Phiel CJ, Klein PS . Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789–813.
Etheridge SL, Spencer GJ, Heath DJ, Genever PG . Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 2004; 22: 849–860.
Xie N, Li H, Wei D, LeSage G, Chen L, Wang S et al. Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis. Neuropharmacology 2010; 59: 444–451.
Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR . Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formos Med Assoc 2011; 110: 487–494.
Parkitna JR, Obara I, Wawrzczak-Bargiela A, Makuch W, Przewlocka B, Przewlocki R . Effects of glycogen synthase kinase 3beta and cyclin-dependent kinase 5 inhibitors on morphine-induced analgesia and tolerance in rats. J Pharmacol Exp Ther 2006; 319: 832–839.
Gault D, Morel-Fatio M, Albert T, Fattal C . Chronic neuropathic pain of spinal cord injury: what is the effectiveness of psychocomportemental management? Ann Phys Rehabil Med 2009; 52: 167–172.
Grandjean EM, Aubry JM . Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder. CNS Drugs 2009; 23: 225–240.
Fahy S, Lawlor BA . Lithium use in octogenarians. Int J Geriatr Psychiatry 2001; 16: 1000–1003.
Grandjean EM, Aubry JM . Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331–349.
Yeung CK, Chan HH . Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3–8.
Acknowledgements
We thank Dr Limin Liao, Dr Lan Sun, Dr Zhigang Chen, Dr Jimin Xu, Ms Mingqin Dong, Dr Xiandi Zhang and Dr Yukun Yang for significant contributions to this phase II clinical study. The study was supported by China Spinal Cord Injury Network Company Limited.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yang, M., Li, J., So, K. et al. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal Cord 50, 141–146 (2012). https://doi.org/10.1038/sc.2011.126
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2011.126
Keywords
This article is cited by
-
Management of central neuropathic pain involves many drugs but few have proven efficacy
Drugs & Therapy Perspectives (2023)
-
Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications
Pharmaceutical Medicine (2023)
-
Coexistence of chronic hyperalgesia and multilevel neuroinflammatory responses after experimental SCI: a systematic approach to profiling neuropathic pain
Journal of Neuroinflammation (2022)
-
The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury
Spinal Cord (2019)
-
Molecular mechanisms underlying the positive role of treadmill training in locomotor recovery after spinal cord injury
Spinal Cord (2017)
